CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	9 Months Ended		185 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Net Loss	$ (13,563)	$ (6,576)	$ (226,971)
Contributions to capital- expenses			100
Issuance of common stock for expenses			8,700
Depreciation and amortization	255	255	29,245
Change in inventory	857	242	(1,597)
Change in accounts payable	9,913	(11,506)	27,566
Net Cash Flows (Used in) Operations	(2,538)	(17,585)	(162,957)
Purchase of patent			(28,650)
Purchase of Equipment-Production Mold			(1,700)
Purchase office equipment			(2,096)
Net Cash Flows (Used in) Investing Activities			(32,446)
Notes Payable from related party	2,725	23,452	64,213
Payments to related party	(187)	(4,946)	(15,522)
Proceeds from the issuance of common stock			146,712
Net Cash Flows provided by Financing Activities	2,538	18,506	195,403
Net Change in Cash		921
Cash at End of Period		921
Issuance of 922,900 common shares for a patent- 2000			11,963
Contributions to capital- expenses- 2001			$ 100